Cue Biopharma, Inc. (CUE) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing injectable therapeutics to modulate T cells for autoimmune diseases and cancer. This report covers the quarterly period ended September 30, 2025. The company operates as a single reporting segment and is currently focused on its CUE-401 (autoimmune) and CUE-500 series (B cell depletion) programs, while its oncology programs (CUE-100 series) have been licensed to partners.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $2,149 | $3,336 | $5,524 | $7,711 |
| Net Loss | $(7,448) | $(8,660) | $(28,187) | $(31,178) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.17) | $(0.31) | $(0.62) |
| Cash & Cash Equivalents | $11,701 | $22,459 | $11,701 | $22,459 |
| Marketable Securities | $6,971 | $0 | $6,971 | $0 |
| Total Liquidity (Cash + Securities) | $18,672 | $22,459 | $18,672 | $22,459 |
| Long-Term Debt (Current Portion) | $1,458 | $4,333 | $1,458 | $4,333 |
| Stockholders' Equity | $13,246 | $25,366 | $13,246 | $25,366 |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by 36% in Q3 2025 compared to Q3 2024 ($2.1M vs. $3.3M). This was primarily due to the termination of the Ono Collaboration and Option Agreement in March 2025, which had generated significant revenue in the prior year, partially offset by revenue from the new Boehringer Ingelheim (BI) agreement.
- Expense Reduction: Research and Development (R&D) expenses dropped significantly to $4.8M in Q3 2025 from $9.4M in Q3 2024, driven by reduced clinical trial costs for the CUE-100 series and lower employee compensation. General and Administrative (G&A) expenses increased to $4.9M from $2.9M, largely due to a one-time employee severance accrual and higher professional fees.
- Financing Activity: The company raised approximately $18.0M in net proceeds from an underwritten public offering in April 2025 and $1.8M via its ATM program in the first nine months of 2025. It also repaid $3.0M of term loans during the period.
- Balance Sheet: Cash and cash equivalents decreased by approximately $10.8M year-over-year. However, the company invested $16.3M in marketable securities during the period, resulting in a total liquidity position of $18.7M as of September 30, 2025.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Based on current plans and expected upfront payments from ImmunoScape (IMSCP), the company believes it can fund operations only into the third quarter of 2026. Substantial additional capital will be required thereafter.
- Strategic Partnerships:
- Boehringer Ingelheim (BI): Received a $10.1M upfront payment (net of withholding tax) in Q2 2025 for the CUE-501 B cell depletion program. Eligible for up to $345M in milestones.
- ImmunoScape (IMSCP): In a subsequent event (Nov 6, 2025), IMSCP exercised an option to license the CUE-100 series (oncology). Cue received $5.0M immediately and is entitled to an additional $10.0M in time-based payments and equity in IMSCP.
- Operational Outlook: The company is preparing to file an Investigational New Drug (IND) application for CUE-401 in Q2 2026. Human safety data is expected in H2 2026, with proof-of-concept data in H2 2027.
- Key Risks:
- Delisting Risk: The company received a deficiency notice from Nasdaq for failing to maintain a $1.00 minimum bid price. It has been granted a compliance period until May 11, 2026, and may effect a reverse stock split to regain compliance.
- Trade Policy: Potential tariffs on pharmaceutical imports and supply chain disruptions due to U.S. trade policy changes.
- Capital Needs: Failure to secure additional financing could force the company to delay or discontinue product development.
Investor Verification Checklist
- Verify the timeline and certainty of the additional $10M in payments from ImmunoScape (IMSCP) to confirm the cash runway extension into Q3 2026.
- Monitor the Nasdaq compliance status regarding the minimum bid price requirement and the potential execution of a reverse stock split.
- Review the specific terms of the Boehringer Ingelheim agreement regarding the $345M in potential milestones and the reimbursement of R&D costs.
- Assess the impact of the one-time severance accrual on future G&A expense trends.
- Confirm the status of the $1.9M German withholding tax receivable related to the BI upfront payment.